NEUROCRINE BIOSCIENCES

NBI-1117568 is a small-molecule therapeutic candidate developed by Neurocrine Biosciences for schizophrenia, currently in Phase 3 clinical development. The program is identified by internal code NBI-1117568-SCZ3031 and represents the company's advancement in the treatment of this serious neuropsychiatric disorder. As of May 2026, the program has reached a significant development milestone, with five active clinical trials registered across multiple study protocols (NCT05545111, NCT06963034, NCT07105098, NCT07114874, NCT07227818). The specific mechanism of action and molecular target remain not yet disclosed. Neurocrine is developing this candidate as a monotherapy approach in a competitive schizophrenia market dominated by established antipsychotics and newer formulations. The May 2026 milestone represents recent progress in the clinical evaluation phase, though specific efficacy, safety, or regulatory outcomes from this milestone have not been disclosed. The program's advancement to Phase 3 with multiple concurrent trials indicates Neurocrine's commitment to addressing unmet needs in schizophrenia treatment, building on the company's existing approved portfolio including Valbenazine for movement disorders.

Schizophrenia remains a significant unmet medical need affecting millions globally, with existing therapies often limited by tolerability, efficacy variability, and adherence challenges. Current treatment options include first-generation and second-generation antipsychotics, long-acting injectables, and adjunctive therapies, yet a substantial proportion of patients experience inadequate symptom control or treatment-emergent adverse effects. The schizophrenia market is highly competitive with multiple approved agents including aripiprazole, paliperidone ER, clozapine, and iloperidone, alongside emerging therapies and formulation innovations. NBI-1117568 enters this landscape as Neurocrine's dedicated schizophrenia program, potentially offering differentiation through its undisclosed mechanism of action and small-molecule profile. The patient population for schizophrenia is substantial, with chronic treatment requirements supporting significant commercial opportunity. Neurocrine's strategic focus on this indication reflects market demand for novel therapeutic approaches that may improve outcomes, reduce side effects, or enhance patient adherence. The progression to Phase 3 with multiple concurrent trials suggests the company has identified a clinically relevant mechanism warranting investment in late-stage development. Success in this program would establish Neurocrine's presence in the core schizophrenia market, complementing its existing movement disorder portfolio and diversifying its revenue streams in neurology and psychiatry.

Drug Class: Small-molecule antipsychotic candidate

Modality: Small molecule

Mechanism of Action: Not yet disclosed

Molecular Target: Not yet disclosed

Route of Administration: Not yet disclosed

Related Therapies: NBI-1117568 competes within the established antipsychotic class, which includes dopamine antagonists (aripiprazole, paliperidone ER), atypical antipsychotics (clozapine, iloperidone), and adjunctive agents (valbenazine for tardive dyskinesia, vortioxetine for cognitive symptoms). Neurocrine's approved product Valbenazine addresses treatment-emergent movement disorders in schizophrenia patients.

First Approval: Not yet approved; Phase 3 stage

Patent Status: Not yet disclosed

• Sponsor: Neurocrine Biosciences Inc.
• Development Partner: None disclosed
• License Type: Not applicable (internally developed)

FDA Status: Not yet disclosed; Phase 3 stage indicates pre-NDA/BLA status

EMA Status: Not yet disclosed

PMDA (Japan) Status: Not yet disclosed

NMPA (China) Status: Not yet disclosed

• Current Development Stage: Phase 3 clinical trials (5 active protocols)
• Regulatory Pathway: Not yet disclosed
• Breakthrough Designation: Not yet disclosed
• Accelerated Approval Eligibility: Not yet disclosed
• Priority Review Status: Not yet disclosed

Regulatory timelines and approval pathways remain not yet disclosed. The presence of multiple Phase 3 trials suggests preparation for regulatory submission, though specific NDA/BLA filing timelines have not been announced.

Strategic Positioning: Neurocrine's advancement of NBI-1117568 to Phase 3 with five concurrent trials indicates significant internal confidence in the candidate's potential. The undisclosed mechanism of action suggests either a novel target or a differentiated approach to dopamine modulation. The May 2026 milestone, while recent, provides limited public visibility into efficacy or safety signals, creating uncertainty regarding competitive positioning.

Competitive Implications: Success would establish Neurocrine as a competitor in the core schizophrenia market, historically dominated by large pharmaceutical companies and specialists. The company's existing Valbenazine approval provides a platform for addressing treatment-emergent adverse effects, potentially enabling a complementary portfolio strategy. However, the mature competitive landscape with multiple approved agents and ongoing innovation in long-acting formulations and adjunctive therapies presents significant barriers to market entry.

Development Risk: The lack of disclosed mechanism, target, or trial design details limits external assessment of clinical differentiation. Phase 3 failure rates in psychiatry remain substantial, and the competitive pressure from established therapies may limit commercial opportunity even with positive efficacy data unless clear advantages in tolerability, efficacy, or patient outcomes are demonstrated.

Future Catalysts: Expected catalysts include Phase 3 trial readouts, regulatory feedback, and potential label expansion strategies leveraging Valbenazine. Timing of NDA/BLA filing and FDA action timelines remain not yet disclosed.